

Sanofi Genzyme partners with patient organizations in India to observe Rare Disease Day 2017

Mumbai – February 26, 2017 -- [Sanofi Genzyme](#), the specialty care global business unit of [Sanofi](#), reiterated its support for Rare Disease Day, by organizing events and activities around the world. This year in India, Sanofi Genzyme partnered with various patients groups like Lysosomal Storage Disorders Support Society, India (LSDSS) and Organization of Rare Diseases India (ORDI), to raise awareness about rare diseases in the country.

It partnered with LSDSS, India, to support programs in major cities like New Delhi, Jaipur and Thiruvananthapuram so as to raise awareness on these debilitating disorders. Sanofi Genzyme also partnered with ORDI for the 'RACE FOR 7' marathon in Bengaluru. At this event, over 3500 people joined steps for 7 kms, by walking and running to symbolically represent the 7000 rare diseases that collectively affect more than 350 million people around the world.

Dr. Shailesh Ayyangar, Managing Director - India and Vice President - South Asia, Sanofi, said, *"Patients with rare diseases often go years without a correct diagnosis. Sanofi Genzyme is dedicated to working together with the patient, physician and research community to shorten this journey to diagnosis, through support of focused education, testing and diagnostic initiatives. Our global vision is to enable all patients with rare diseases with access to early diagnosis and appropriate treatment by 2025."*

Observed annually on the last day of February, Rare Disease Day is an international awareness campaign established by the European Organisation for Rare Diseases (EURORDIS) in 2008, and supported by hundreds of other patient organizations. This day provides an opportunity to shed light on the impact that these frequently debilitating diseases have on patients and their families. Given their rarity, these conditions are often difficult to diagnose and treat. Patients can endure a long odyssey involving many specialty doctors, tests, and numerous misdiagnoses.

This year, Sanofi Genzyme also launched a global initiative called [Pledge 4 Rare](#), aimed at bringing together the global rare disease community to raise awareness on rare diseases. The campaign encourages people to pledge to run or walk a mile or more on Rare Disease Day in support of the rare disease community, and to share photos and videos on social media using the hashtag #Pledge4Rare.

About Sanofi

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organized into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare.

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Sanofi Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi's ability to benefit from external growth opportunities and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation, trends in exchange rates and prevailing interest rates, volatile economic conditions, the impact of cost containment initiatives and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2015. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations

Aparna Thomas

Tel.: +91 22 2803 2169

aparna.thomas@sanofi.com

Sohil Bahamania

Tel: +91 22 2803 2446

sohil.bahamania@sanofi.com